Everest Medicines, a China in-licensing company, reported positive top-line safety results from a China Phase I trial of taniborbactam in multi-drug resistant (MDR) pathogens.  Taniborbactam was tested in combination with cefepime. Everest acquired rights to cefepime-taniborbactam in Greater China and southeast Asia from VenatoRx of Pennsylvania. The two companies are conducting a pivotal Phase III trial of the cefepime-taniborbactam combination in patients with complicated urinary tract infection (cUTI). More details.... Share this with colleagues: // //